Clinical trial
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell…
NCT00066352 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00066352 |
|---|---|
| Title | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter |
| Official title | A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis) |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Sep 1, 2003 |
| Primary completion | Sep 1, 2003 |
| First posted | Aug 7, 2003 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: